Anticholeric vaccines and vaccination;Vaccins et vaccination anticholériques

Bulletin de la Societe de Pathologie Exotique

Volumn 95, Issue 5, 2003, Pages 355-358

  Ivanoff, B ^a   Chaignat, C L ^b  

^a International Vaccine Institute   (South Korea)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Attenuated vaccine; Cholera; Inactivated vaccine; Oral route; Serogroup O1; Serogroup O139; Sub unit vaccine

Indexed keywords

CHOLERA VACCINE;

ARTICLE; CHOLERA; CONTROLLED STUDY; DEVELOPING COUNTRY; DIARRHEA; DRUG RESEARCH; HUMAN; POPULATION; REFUGEE; VACCINATION;

CAUSE OF DEATH; CHOLERA; CHOLERA VACCINES; COST OF ILLNESS; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; HUMANS; POPULATION SURVEILLANCE; POVERTY; REFUGEES; RISK FACTORS; SANITATION; TRAVEL; VACCINATION; WATER MICROBIOLOGY;

EID: 0345268663     PISSN: 00379085     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. AREHAWARATANA PS, SINGHARAJ P, TAYLOR N, HOGE C, TROFA A et al.- Safety and Immunogenicity of Different Immunization Regimens of CVD103HgR Live Oral Vaccine in Soldiers and Civilians in Thailand. J Infect Dis, 1992, 164, 1042-1048.
2. BENITEZ J, GARCIA L, SILVA A, GARCIA H, FANDO R et al.- Preliminary assessment of the safety and immunogenicity of a new CTX phage negative, hemagglutinin/protease defective EI Tor strain as a cholera vaccine candidate. Infect Immun, 1999, 67, 539-545.
3. BERCHE P & IVANOFF B - Vers la huitième pandémie de choléra. Presse Méd, 1994, 23, 872-873.
4. BLACK R.E, LEVINE B, CLEMENS ML, YOUNG CR, SVENNERHOLM AM & HOLMGREN J - Protective efficacy in human of killed whole Vibrio-oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun, 1987, 55, 1116-1120.
5. BOUTONNIER A, VILLENEUVE S, NATO F, DASSY B & FOURNIER JM - Preparation, immunogenicity and protective efficacy in a murine model, of conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect Immun, 2001, 69, 3488-3493.
6. GUPTA R, TAYLOR D, BRILA D, ROBBINS JB & SZU SC - Phase I evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide cholera toxin conjugates in adult volunteers. Infect Immun, 1998, 66, 3095-3099.
7. IVANOFF B & CLEMENS J - Caractéristiques épidémiologiques, cliniques et microbiologiques de la nouvelle souche de Vibriocholerae O139. Méd Trop, 1994, 54, 75-77.
8. KOLLARITSCH H, QUE JU, KUNZ C, WIEDERMAN G, HERZOG C & CRYZ SJ - Safety and Immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine or yellow fever vaccine. J infect Dis, 1997, 175, 871-875.
9. KOTLOFF KI, WASSERMAN SS, O'DONNELL S, LOSONSKY GA, KAPER JB & SRIVASTAVA BS - Safety and immunogenicity in North Americans of a single dose of live Oral cholera vaccine CVD103HgR: Results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun, 1992, 60, 4430-4432.
10. LEVINE MM, KAPER JB, HERRINGTON D, KETLEY J, LOSONSKY G et al.- Safety immunogenicity and efficacy of recombinant live oral cholera vaccine CVD103 and CVD103-HgR. Lancet, 1988, 2, 467-470.
11. OMS - Potential use of oral cholera vaccines in emergency situations Report WHO meeting Geneva (12-13 May 1999).
12. RAMAMURTHY T, GARG S, SHARMA R, BHATTACHARYA SK, NAIR GB, SHIMADA T et al.- Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet, 1993, 341, 703-704.
13. RICHIE E, PUNJABI N, SIDHARTA Y, PEETOSUTAN K, SUKANDAR M et al.- Efficacy trial of single-dose live oral cholera vaccine CVD103HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine, 2000, 18, 2399-2410.
14. SANCHEZ JL, VASQUEZ B, BEGUE RE, MEZA R, CASTELLARES G et al.- Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet, 1994, 344, 1273-1275.
15. SIMANJUTAK SC, WITHAM N, PUNJABI N, HEPPNER DG, LOSONSKY G et al.- Safety and Immunogenicity of single dose live oral cholera vaccine CVD103HgR in 5-9 years old Indonesian children. Lancet, 1992, 340, 689-694.
16. TACKET CO, LOSONSKY G, NATARO JP, MICHALSKY J, KAPER JB & LEVINE MM - Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD103HgR. J Infect Dis, 1992, 166, 837-841.
17. TRACH DD, CAM PD, KE NT, RAO MR, DINH D et al.- Investigations of the safety and immunogenicity of a new killed oral cholera vaccine developed in Vietnam. Bull Org Mond Santé, 2002, 80, 2-8.
18. TRACH DD, CLEMENS JD, KE NT, THUY HT, SON ND et al.- Field trial of a locally produced, killed, oral cholera vaccine in Viet Nam. Lancet, 1997, 349, 231-235.
19. VALLE E, LEDON T, CEDRE B, CAMPOS J, VALMASEDA T et al.-Construction and characterization of a nonproliferative El Tor cholera vaccine candidate derived from strain 638. Infect Immun, 2000, 68, 6411-6418.
20. WALDOR MK, WOODS A, PEARSON DN, SADOFF J & MEKALANOS JJ - Molecular analysis of novel Vibrio cholerae strains and development of live vaccines prototypes. J Infect Dis, 1994, 170, 278-283.
21. WALDOR MW & MEKALANOS JJ - ToxR regulates virulence gene expression in non-O1 strains of Vibrio cholerae that cause epidemic cholera. Infect Immun, 1994, 62, 72-78.